Stargazer Pharmaceuticals, a biopharmaceutical company focused on the development of novel treatment options for rare eye diseases, announced it has completed a Series A financing. Totaling $57 million, the Series A round came from Novo Holdings, venBio Partners, Canaan Partners and Pontifax to develop its proprietary compound STG-001 for treating Stargardt Disease.

Stargazer is collaborating with Foundation Fighting Blindness (FFB), which participated in this financing round via their investment vehicle, the Retinal Degeneration Fund. Stargardt Disease is a genetic orphan disease that leads to legal blindness. It is the most common juvenile macular dystrophy affecting 1 in 8,000 to 1 in 10,000 individuals. There are currently no therapies available for this disease.

Stargazer Pharmaceuticals, Inc., is a Boston-based biopharmaceutical drug development company launched in 2018 with a focus on rare diseases of the eye, and an initial focus on Stargardt Disease.